Sarepta Therapeutics (SRPT) Eteplirsen Gains Coverage at Aetna
- Wall Street dips as investors ready for Trump's inauguration
- Western Union (WU) Admits Anti-Money Laundering and Consumer Fraud Violations, Forfeits $586M in Settlement
- Netflix, Inc. (NFLX) Tops Q4 EPS by 1c; Subs Beat Views
- Apple (AAPL) PT Raised to $140 at BofA/Merrill Lynch; iPhone 8 Will be 'Super-Long' Cycle
- Morgan Stanley Upgrades Tesla Motors (TSLA) to Overweight
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sarepta Therapeutics (SRPT) Exondys 51 requires "review of drug and site of care required" at Aetna
- Shire (SHPG) Says FDA Acknowledges Receipt of NDA for SHP465 for ADHD
- Immunomedics (IMMU): New IMMU-132 Data at Investor R&D Day
Create E-mail Alert Related CategoriesFDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!